VCYT Stock Overview
Operates as a diagnostics company in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Veracyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$32.14 |
| 52 Week High | US$47.32 |
| 52 Week Low | US$18.61 |
| Beta | 2.04 |
| 1 Month Change | 2.00% |
| 3 Month Change | -21.72% |
| 1 Year Change | 65.93% |
| 3 Year Change | 38.18% |
| 5 Year Change | 38.06% |
| Change since IPO | 142.57% |
Recent News & Updates
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality
Mar 08
Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Mar 04Recent updates
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality
Mar 08Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Mar 04Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price
Jan 09Veracyte: Getting Frothy
Dec 11Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Dec 01Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%
Aug 18Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Aug 09Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price
Jul 02Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking
Jun 06Veracyte, Inc. (NASDAQ:VCYT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 09Lacklustre Performance Is Driving Veracyte, Inc.'s (NASDAQ:VCYT) Low P/S
Apr 18A Look At The Intrinsic Value Of Veracyte, Inc. (NASDAQ:VCYT)
Mar 18Veracyte Percepta Genomic Sequencing Classifier demonstrates accuracy in lung cancer risk
Jul 13Shareholder Returns
| VCYT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.8% | 4.9% | 6.8% |
| 1Y | 65.9% | -8.0% | 5.9% |
Return vs Industry: VCYT exceeded the US Biotechs industry which returned -11.3% over the past year.
Return vs Market: VCYT exceeded the US Market which returned 4.8% over the past year.
Price Volatility
| VCYT volatility | |
|---|---|
| VCYT Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: VCYT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VCYT's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 824 | Marc Stapley | www.veracyte.com |
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It is also developing the nCounter analysis system services.
Veracyte, Inc. Fundamentals Summary
| VCYT fundamental statistics | |
|---|---|
| Market cap | US$2.48b |
| Earnings (TTM) | US$24.14m |
| Revenue (TTM) | US$445.76m |
103.8x
P/E Ratio5.6x
P/S RatioIs VCYT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VCYT income statement (TTM) | |
|---|---|
| Revenue | US$445.76m |
| Cost of Revenue | US$136.07m |
| Gross Profit | US$309.70m |
| Other Expenses | US$285.56m |
| Earnings | US$24.14m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.31 |
| Gross Margin | 69.48% |
| Net Profit Margin | 5.42% |
| Debt/Equity Ratio | 0% |
How did VCYT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/14 13:48 |
| End of Day Share Price | 2025/04/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Veracyte, Inc. is covered by 19 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sung Ji Nam | BTIG |
| Bryan Brokmeier | Cantor Fitzgerald & Co. |
| William Bonello | Craig-Hallum Capital Group LLC |